|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Dental Medicine / Faculty of Dental Medicine >
Peer-reviewed Journal Articles, etc >
Inhibitory effects of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated endothelial cells and endothelial progenitor cells
| Title: | Inhibitory effects of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated endothelial cells and endothelial progenitor cells |
| Authors: | Ohga, Noritaka Browse this author | | Hida, Kyoko Browse this author →KAKEN DB | | Hida, Yasuhiro Browse this author | | Muraki, Chikara Browse this author | | Tsuchiya, Kunihiko Browse this author | | Matsuda, Kohei Browse this author | | Ohiro, Yoichi Browse this author | | Totsuka, Yasunori Browse this author | | Shindoh, Masanobu Browse this author |
| Issue Date: | Oct-2009 |
| Publisher: | Wiley-Blackwell |
| Journal Title: | Cancer Science |
| Volume: | 100 |
| Issue: | 10 |
| Start Page: | 1963 |
| End Page: | 1970 |
| Publisher DOI: | 10.1111/j.1349-7006.2009.01255.x |
| Abstract: | The polyphenol epigallocatechin-3 gallate (EGCG) in green tea suppresses tumor growth by direct action on tumor cells and by inhibition of angiogenesis, but it is not known whether it specifically inhibits tumor angiogenesis. We examined the anti-angiogenic effect of EGCG on tumor-associated endothelial cells (TECs), endothelial progenitor cells (EPCs), and normal endothelial cells (NECs). EGCG suppressed the migration of TECs and EPCs but not NECs. EGCG also inhibited the phosphorylation of Akt in TECs but not in NECs. Furthermore, vascular endothelial growth factor-induced mobilization of EPCs into circulation was inhibited by EGCG. Matrix metalloproteinase-9 (MMP-9) in the bone marrow plasma plays key roles in EPC mobilization into circulation. We observed that expression of MMP-9 mRNA was downregulated by EGCG in mouse bone marrow stromal cells. In vivo model, EGCG suppressed growth of melanoma and reduced microvessel density. Our study showed that EGCG has selective anti-angiogenic effects on TECs and EPC. It is suggested that EGCG could be a promising angiogenesis inhibitor for cancer therapy. |
| Rights: | The definitive version is available at www.blackwell-synergy.com |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/43937 |
| Appears in Collections: | 歯学院・歯学研究院 (Graduate School of Dental Medicine / Faculty of Dental Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 樋田 京子
|
